It is clear that GLP‐1 receptor mimetics have had a dramatic and positive impact on diabetes and obesity treatment regimens within a relatively short time period, and we await further progress on the therapeutic utility of GLP‐1‐based drugs with real optimism. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.